Molecular Partners (MOLN) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on DARPin therapeutics, a novel class of protein drug candidates designed for multi-functionality and multi-target specificity, addressing medical challenges unmet by other modalities.

• DARPin candidates have been tested in over 2,500 patients, showing high activity and general tolerability.

• Founded in 2004, with senior management and board members experienced in major pharmaceutical companies and active collaborations, including with Orano Med.

Financial performance and metrics

• Financial statements are prepared in accordance with IFRS as issued by the IASB, not U.S. GAAP.

• As of April 9, 2025, share capital was CHF 4,036,309.50, consisting of 40,363,095 ordinary shares with a nominal value of CHF 0.10 each.

• Share capital has increased through conditional and authorized capital mechanisms, with recent issuances for employee participation and fundraising.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for pipeline development, general corporate purposes, investments, acquisitions, collaborations, and working capital.

• Management retains broad discretion over allocation and timing of expenditures; proceeds may be temporarily invested in capital preservation instruments.